Long-term study of antiphospholipid syndrome
Part of Immune system & allergy clinical trials.
This trial follows patients with antiphospholipid syndrome over time to learn more about the condition. It may help researchers understand how the disease progresses and how to better manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have antiphospholipid syndrome as defined by the 2006 Sydney criteria (a specific set of medical guidelines).
- You cannot have a condition that does not meet these criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study looks at people with antiphospholipid syndrome (APS) who have taken or are taking direct oral anticoagulants (DOACs), which are blood thinners. The goal is to collect information about their treatment and health over time.
This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.
This study compares two types of blood thinners (DOACs like rivaroxaban/apixaban vs. warfarin) in people with antiphospholipid syndrome who have had a vein clot. The goal is to see which works better to prevent future clots.
This study looks at lab results and clinic information in people who have antiphospholipid antibodies. The goal is to better understand these antibody-positive conditions and what happens over time, which may help improve care.
This study looks for a blood clotting disorder called antiphospholipid syndrome (APS) in people aged 65 and older who have had a stroke or a mini-stroke (TIA). The goal is to understand how common APS is in this group and if it affects recovery.
This study looks at people who test positive for antiphospholipid antibodies on more than one blood test. It helps researchers better understand the condition and how to follow patients over time.
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.